Evidence map›Paper›PMID 21248159›Full record

ArticleClinical and vaccine immunology : CVI2011

Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults.

H Findlow, R Borrow, P Hardelid, E Newton, S Frankland, S Naylor, E Miller, E Kaczmarski, R C Read

Open access · diamondAbstract read
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

H FindlowVaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom. Helen.findlow@hpa.org.uk
R Borrow
P Hardelid
E Newton
S Frankland
S Naylor
E Miller
E Kaczmarski
R C Read
Manchester Royal Infirmary · GBPublic Health England · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limited data are available on the kinetics of meningococcal serogroup C (MenC)-specific antibody responses following parenteral or nasal challenge in those who have received prior MenC vaccination (polysaccharide or conjugate). Young adults who had previously received either meningococcal A/C polysaccharide (MACP) or MenC conjugate (MCC) vaccine or naïve subjects were challenged with MACP via one of two routes, nasal or parenteral. Blood samples were taken prevaccination and on days 1 to 4 and day 10 postvaccination. MenC serum bactericidal antibody (SBA) and MenC-specific IgG were measured. Following parenteral challenge, MenC SBA and IgG responses were seen to occur between 4 and 7 days postchallenge. A lower proportion of subjects responded following nasal challenge, with naïve subjects showing little change in SBA geometric mean titer (GMT) and IgG geometric mean concentration (GMC) over the 10 days following challenge. Increases in SBA GMTs were seen between 4 and 7 days after nasal challenge in those who had received prior MCC and between 7 and 10 days in those who had received prior MACP, and the responses in the prior-MACP group were of lower magnitude than the responses of the prior-MCC group. The data presented here indicate that, following MCC vaccination, memory has been induced at the mucosal level, and these subjects were able to respond with increases in SBA levels. These results demonstrate that the speed of response (primary or secondary) to challenge with MenC polysaccharide via the nasal or parenteral route does not differ and support concerns that immunological memory alone is too slow to provide protection.

Indexed as

Administration, IntranasalAdultAntibodies, BacterialBlood Bactericidal ActivityFemaleHumansImmunoglobulin GImmunologic MemoryInjections, IntravenousMaleMeningococcal VaccinesNeisseria meningitidis, Serogroup CPolysaccharides, BacterialTime FactorsAntibodies, BacterialImmunoglobulin GMeningococcal VaccinesPolysaccharides, Bacterial

Identifiers

PMID21248159
PMCPMC3067375
OpenAlexW2118963825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.